Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 17/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 17/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456324 | 0.96 | BCL9 (0.59) | BCL9CTNNB1PDE4BJAK2JAK3 | |
| SCHEMBL30392565 | 0.91 | BCL9 (0.62) | BCL9CTNNB1 | |
| SCHEMBL19404225 | 0.91 | BCL9 (0.62) | BCL9CTNNB1 | |
| SCHEMBL30392512 | 0.90 | BCL9 (0.66) | BCL9CTNNB1 | |
| SCHEMBL30392258 | 0.90 | BCL9 (0.66) | BCL9CTNNB1 | |
| SCHEMBL23456173 | 0.88 | BCL9 (0.51) | BCL9CTNNB1PDE4B | |
| SCHEMBL23456174 | 0.88 | BCL9 (0.51) | BCL9CTNNB1PDE4B | |
| SCHEMBL23456258 | 0.87 | BCL9 (0.59) | BCL9CTNNB1 | |
| SCHEMBL23456244 | 0.87 | BCL9 (0.62) | BCL9CTNNB1 | |
| SCHEMBL23456242 | 0.87 | BCL9 (0.62) | BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-04-29 | — | — | US | disclosed |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 6/4885PDE4B 3468/4885 |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 6/4885PDE4B 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.